Search results
Showing 241 to 255 of 300 results for breast cancer
Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]
In development [GID-TA10592] Expected publication date: TBC
Bevacizumab for the first-line treatment of metastatic breast cancer (TA147)
This appraisal has been updated and replaced by NICE technology appraisal 214.
Eribulin for the treatment of locally advanced or metastatic breast cancer (TA250)
This guidance has been updated and replaced by NICE technology appraisal guidance 423 and NICE technology appraisal guidance 515.
Suspected sepsis: recognition, diagnosis and early management (NG51)
This guideline covers the recognition, diagnosis and early management of suspected sepsis. It includes recommendations on recognition and early assessment, initial treatment, escalating care, finding and controlling the source of infection, early monitoring, information and support, and training and education.
Show all sections
Sections for NG51
- Overview
- Could this be sepsis?
- Face to face assessment
- Under 16s: evaluating risk and managing suspected sepsis
- Pregnant or recently pregnant people: evaluating risk and managing suspected sepsis
- Over 16s (not pregnant or recently pregnant): evaluating risk and managing suspected sepsis
- Antibiotic therapy, intravenous fluid and oxygen
- Finding and controlling the source of infection
Paclitaxel for the adjuvant treatment of early node-positive breast cancer (TA108)
This guideline has been updated and replaced by NICE guideline NG101. Docetaxel for the adjuvant treatment of early node-positive breast cancer (TA109)
This guideline has been updated and replaced by NICE guideline NG101. Interim methods guide for developing service guidance 2014 (PMG8)
Interim methods guide for developing service guidance 2014
Early breast cancer (preventing recurrence and improving survival): adjuvant bisphosphonates (ES15)
This evidence summary has been updated and replaced by NICE guideline NG101.
Guidance on the use of vinorelbine for the treatment of advanced breast cancer (TA54)
This guidance has been updated and replaced by NICE guideline CG81.
This guideline covers behaviours such as diet and physical activity to help children (after weaning), young people and adults maintain a healthy weight or help prevent excess weight gain. The aim is to prevent a range of diseases and conditions including cardiovascular disease and type 2 diabetes and improve mental wellbeing.
Evidence-based recommendations on tacrolimus (Protopic) and pimecrolimus (Elidel) for people with atopic eczema.
Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer (TA107)
This guideline has been updated and replaced by NICE guideline NG101. EndoPredict gene expression profiling assay for assessing risk of breast cancer recurrence (MIB44)
This advice has been updated and replaced by NICE diagnostics guidance 34.
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG34)
This guidance has been updated and replaced by NICE diagnostics guidance 58.
This guideline has been updated and replaced by NICE guideline NG101.